| Name | SEL120-34A |
| Description | SEL120-34A is a selective and ATP-competitive inhibitor of CDK8 with IC50s of 4.4 nM, 10.4 nM and 1070 nM for CDK8/CycC, CDK19/CycC and CDK9/cycT. SEL120-34A possesses antitumor activity. |
| In vitro | SEL120-34A shows no obvious inhibition on CDK1, 2, 4, 6, 5, 7. SEL120-34A weakly suppresses CDK9 with an IC50 of 1070 nM. SEL120-34A is active against a panel of AML cell lines including KG-1, SKNO-1, HEL-60, MOLM-16, OciAML-2, MV-4-11, MOLM-6 and OciAML-3 cells with GI50<1 μM[1]. |
| In vivo | SEL120-34A (30 mg/kg and 60 mg/kg; p.o.) inhibits the growth of tumors in mice bearing MV4-11 cancer cells. SEL120-34A (30 mg/kg; p.o.) arrests the growth of KG-1-derived tumors[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 4.15 mg/mL (10.02 mM), Sonication is recommended. H2O : < 0.65 mg/mL (1.56mM)(insoluble)
|
| Keywords | SEL120-34A | SEL-120-34A | SEL12034A | SEL120 34A | CDK9/cycT | CDK8/CycC | CDK19/CycC |
| Inhibitors Related | Ribociclib | (E)-β-Farnesene | Amantadine | 2-Chloropyrazine | Kojic acid | Abemaciclib | 2,4,6-Trihydroxybenzoic acid | Palbociclib | Abemaciclib methanesulfonate | Sodium Oxamate | Seliciclib | Dinaciclib |
| Related Compound Libraries | Bioactive Compound Library | ReFRAME Related Library | Kinase Inhibitor Library | Anti-Breast Cancer Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Anti-Aging Compound Library | Clinical Compound Library | Bioactive Compounds Library Max | Anti-Cancer Active Compound Library | Anti-Cancer Drug Library |